Macrophage-derived CXCL9 and CXL10 have been recognized as markers for an improved response to immunotherapy in melanoma patients, and are required for the efficacy of immunotherapy in murine syngeneic models of MC38 (colon cancer), AT-3, E0771 (breast cancer), and B16F10 (melanoma) models [96]. This evidence concerns the gene CXCL9 and malignant colon neoplasm.